Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Saptak Chem and Business Ltd's Board, meeting on January 13, 2026, approved the allotment of 40,00,000 (Forty Lakhs) convertible equity warrants to 8 non-promoter allottees (individuals, HUFs, and LLPs) on a preferential basis at ₹10.50 per warrant, aggregating to ₹4.20 crore in total potential consideration. The company has already received 25% upfront (₹1.05 crore), with the balance 75% (₹3.15 crore) payable upon conversion within 18 months. Each warrant is convertible into one equity share of face value ₹10. Since these are warrants and not shares, there is no immediate change in paid-up share capital. None of the allottees held shares prior to this issue. If all warrants are converted, the 8 allottees would collectively hold 78.85% of the post-diluted share capital.
Existing shareholders face significant dilution risk — if all warrants convert, the 8 new non-promoter allottees will collectively own nearly 79% of the company on a diluted basis. While no immediate equity dilution occurs since warrants (not shares) are issued, this is a major change in ownership structure and could weigh on the stock in the short term due to potential supply overhang on conversion.